Whilst KRAS mutations occur early in the pathogenesis of pancreatic cancer and TP53 and SMAD4 mutations occur later, CDKN2A mutations occur as an intermediate event (Fukushima et al. 2002; Romagosa et al. 2011) (Fig. 1). This evidence concerns the gene CDKN2A and pancreatic neoplasm.